NCT06772415招募中1 期
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral KIF18A Inhibitor GenSci122 in Participants With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 163
- 试验地点
- 9
- 主要终点
- Dose escalation: Incidence of dose-limiting toxicities (DLTs).
研究概览
简要总结
This is a first-in-human (FIH), multicenter, open-label, phase I study to evaluate the safety, tolerability, PK and preliminary efficacy of GenSci122 in participants with advanced solid tumors. The study consists of 2 parts: Part 1- dose-escalation and Part 2- dose expansion. The primary endpoint of Dose escalation is To assess the safety and tolerability of GenSci122. The primary endpoint of Dose expansion is to evaluate the preliminary anti-tumor activity of GenSci122 in participants with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide informed consent and sign the informed consent form (ICF).
- •Male or female participants ≥18 years old at the time of consent.
- •Meeting the requirements of tumor types shown below:
- •Dose escalation:
- •Participants with a histological or cytological diagnosis of recurrent or metastatic advanced solid tumors who have failed or are intolerant to standard treatment, or have no standard therapy.
- •Dose expansion:
- •Participants with a histological or cytological diagnosis of recurrent or metastatic advanced solid tumors who have failed or are intolerant to standard treatment, or have no standard therapy.
- •Participants agree to provide fresh or archived tumor tissue as well as corresponding pathological report.
- •Survival expectations are ≥ 12 weeks.
- •Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1 (Appendix 1).
- •At least one measurable target lesion
- •Participants with adequate organ function at the time of screening (requiring no blood transfusion, no use of hematopoietic stimulating factor or human albumin or use of drug for correction within 14 days before the first dose)
- •All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1
- •Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence and must have resolved completely.
- •Normal QT interval on screening ECG evaluation
- •Participants with a known HIV infection are eligible if the following criteria are met:
- •a. Stable on antiretroviral therapy for ≥ 4 weeks before the first dose of GenSci
- •d. Viral load of < 400 copies per mL at screening. e. CD4+ T-cell count ≥ 350 cells/μL at screening.
- •Hepatitis B virus (HBV) and hepatitis C virus (HCV) test is negative. If participants have active HBV infection: HBV- deoxyribonucleic acid (DNA) must be < 500 IU/mL (or must be < 2500 copy/mL if copy/mL is the only unit available in the study site) and are willing to receive antiviral therapy throughout the study (treatment in accordance with local standard of care, e.g., entecavir); participants with positive HCV ribonucleic acid (RNA) must receive antiviral therapy in accordance with the local standard treatment guideline and have ≤ CTCAE 5.0 Grade 1 elevated hepatic function.
- •Women of childbearing potential (WOCBP) must have a serum pregnancy test negative within 7 days before the first dose of GenSci
- •WOCBP must agree to avoid pregnancy during the study and agree to the use 2 effective contraceptive methods (hormonal or barrier method of birth control, or abstinence) before study entry, for the duration of study participation, and in the following 6 months after discontinuation of Gensci122
- •Men with a partner(s) of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 3 months after discontinuation of GenSci122 and to use appropriate barrier contraception or abstinence
排除标准
- •Investigational agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) before the first dose of GenSci
- •In addition, no concurrent investigational anti-cancer therapy is permitted.
- •Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of GenSci
- •Radiotherapy within 4 weeks before the first dose of GenSci
- •Or participants have not yet recovered from acute effects of radiotherapy to baseline before the first dose of GenSci
- •Symptomatic primary central nervous system (CNS) tumor, metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression.
- •Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months before the first dose of GenSci
- •Active uncontrolled systemic bacterial, viral, or fungal infection, or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. Screening for chronic conditions is not required.
- •Inability to swallow pills or clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of GenSci
- •Pregnancy or lactation.
- •History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma, for which by the date of the first dose of GenSci122, at least 3 years of complete remission and no other treatment is needed or expected during the study period.
- •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse
- •Allergic to GenSci122 tablet or its components.
- •Any serious illness, uncontrolled inter-current illness, psychiatric illness, or other medical history, including lab results, which in the opinion of investigator or medical monitor would be likely to impact safety or compliance with study requirements or confounds the ability to interpret the data.
- •Has a treatment history of KIF18A inhibitor.
- •Participants with DNA polymerase epsilon (POLE) gene hotspot mutated, or hypermutator phenotype.
- •Other conditions that are not eligible for inclusion based on the investigator's judgment.
研究组 & 干预措施
Single arm
Experimental
干预措施: GenSci122 tablet 50mg (Drug)
Single arm
Experimental
干预措施: GenSci122 tablet 250mg (Drug)
结局指标
主要结局
Dose escalation: Incidence of dose-limiting toxicities (DLTs).
时间窗: 2 years
Dose expansion: Objective response rate (ORR) evaluated by investigator based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
时间窗: 3 Years
次要结局
- Incidence and severity of TEAEs.(3 years)
- Maximum Plasma Concentration (Cmax) of Gensci122(3 years)
- Duration of Response (DOR)(3 years)
- Progression-free Survival (PFS)(3 years)
- Overall Survival (OS)(3 years)
- Time to Maximum Plasma Concentration (Tmax) of Gensci122(3 years)
- Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for Gensci122(3 years)
研究者
研究点 (9)
Loading locations...
相似试验
招募中
1 期
Safety and Efficacy of BA1302 in Patients With Advanced Solid TumorsPancreatic AdenocarcinomaBreast CancerMelanomaNon-Small Cell Lung CancerNCT06596915Shandong Boan Biotechnology Co., Ltd167
终止
1 期
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative NeoplasmAcute Myeloid LeukemiaNCT04637009Astex Pharmaceuticals, Inc.20
已完成
1 期
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant NeoplasmAdvanced TumorsNCT05429008Hutchmed40
招募中
1 期
A Study of FZ-AD005 in Patients With Advanced Solid TumorsAdvanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)NCT06424665Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.162
Enrolling By Invitation
1 期
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsNCT06115642Shanghai Henlius Biotech367